Pharmaceutical

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

The takeover, which includes the candidate felzartamab, for immune-mediated diseases, diversifies Biogen’s scope.

Jul 4, 2024 - 04:00
Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence
The takeover, which includes the candidate felzartamab, for immune-mediated diseases, diversifies Biogen’s scope.
Read the original article

Tags:

Previous Article

Beacon secures $170m to advance ophthalmic gene therapies

Next Article

Emergent scores US medical countermeasure contracts worth over $250m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

In North Carolina, a radical experiment targets social determinants of health with fresh produce and safe housing

In North Carolina, a radical experiment targets social ...

Sep 22, 2023

Opinion: STAT+: 3 keys to successful biopharma-academia drug development collaborations

Opinion: STAT+: 3 keys to successful biopharma-academia...

Apr 1, 2023

Yield10 Bioscience gets grant for genetically engineere...

Mar 30, 2024